ASCO: Merck, Kelun's sac-TMT ADC combo beats Keytruda by 65% on progression in first-line lung cancer

According to an abstract released ahead of the ASCO 2026 annual meeting, combining the TROP2-directed ADC with Keytruda slashed the risk of disease progression or death by a whopping 65% compared with Keytruda alone in treatment-naïve, PD-L1-positive non-small cell lung cancer.